Matinas BioPharma Holdings (MTNB) Earning Somewhat Favorable Press Coverage, Study Finds

Xavier Trudeau
Août 11, 2017

Matinas BioPharma Holdings Inc (NASDAQ:MTNB) has been given a $9.00 price target by investment analysts at Roth Capital in a research note issued to investors on Thursday.

A number of equities analysts have commented on MTNB shares. The firm had revenue of $0.02 million during the quarter.

Among 2 analysts covering MATINAS BIOPHA... 167,204 shares of the company traded hands. The firm's market capitalization is $125.21 million. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma Holdings, Inc. with MarketBeat.com's FREE daily email newsletter.

Separately, Maxim Group set a $6.00 price objective on shares of Matinas BioPharma Holdings and gave the stock a "buy" rating in a report on Tuesday, May 16th.

Separately, Roth Capital initiated coverage on shares of Matinas BioPharma Holdings in a research note on Monday, July 10th. The company has a 50-day moving average price of $1.66 and a 200-day moving average price of $2.56. The company reported ($0.04) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.01. Matinas BioPharma Holdings had a negative return on equity of 1,227.85% and a negative net margin of 30,034.20%. Currently, 7.2% of the company's shares are sold short.

TRADEMARK VIOLATION NOTICE: "Matinas BioPharma Holdings Inc (MTNB) Sees Significant Increase in Short Interest" was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally copied and republished in violation of U.S. & worldwide copyright & trademark legislation. Bank of New York Mellon Corp acquired a new position in shares of Matinas BioPharma Holdings during the second quarter worth approximately $282,000. Hyman Charles D acquired a new stake in Matinas BioPharma Holdings during the first quarter valued at $221,000. Spark Investment Management LLC bought a new position in shares of Matinas BioPharma Holdings during the first quarter valued at about $105,000. IFP Advisors Inc acquired a new position in shares of Matinas BioPharma Holdings during the second quarter worth approximately $1,183,000. Segantii Capital Management Ltd acquired a new stake in shares of Matinas BioPharma Holdings during the first quarter valued at $166,000.

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. Its pipeline develops fungal infections, vulvovaginal candidiasis, tolerability in hematologic malignancy, gram-negative bacterial infections, chronic and acute bacterial infections formulations.

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL